Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors

NCT07570745 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Graft-Versus-Host Disease(GVHD)
Bone Marrow Transplantation

Interventions

DRUG: Low-dose ATG + PTCy + Ivarmacitinib

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine